Drugs / Ad26.Mos.HIV
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02685020 | Mar 2016 → Jan 2018 | — | Janssen Vaccines & Prevention B.V. | Completed | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT02919306 | Sep 2016 → Sep 2018 | HIV infectious disease | Janssen Vaccines & Prevention B.V. | Completed | No outcome recorded |
| Phase 1/2 | NCT02788045 | Jul 2016 → Apr 2022 | — | Janssen Vaccines & Prevention B.V. | Completed | No outcome recorded |
| Phase 1/2 | NCT02315703 | Dec 2014 → Aug 2017 | — | Janssen Vaccines & Prevention B.V. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ad26.Mos.HIV | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02919306 ↗ |
| Modality | Vaccine | “Recombinant replication-deficient Ad26 vectored vaccine” NCT02315703 ↗ |
| Route | Intramuscular | “administered intramuscularly” NCT02315703 ↗ |